Vitexin / NRF2 Cancer Research Results

VT, Vitexin: Click to Expand ⟱
Features:

Vitexin - Apigenin-8-C-Glucoside

Alternative Names: Apigenin-8-C-glucoside, apigenin-8-C-β-D-glucopyranoside

Type: Flavone C-glycoside / apigenin derivative

Function: Vitexin is a naturally occurring C-glycosylated flavone in which glucose is attached to apigenin at the C-8 position. It exhibits antioxidant, anti-inflammatory, metabolic, cardiovascular, neuroprotective, and antiproliferative activities and can modulate pathways involving NF-κB, Nrf2/HO-1, MAPK, PI3K/AKT, AMPK, HIF-1α, apoptosis, and oxidative stress.

-see also IsoVitexin

Cancer: Preclinical studies indicate antiproliferative, pro-apoptotic, anti-migratory, anti-invasive, and anti-inflammatory effects across multiple cancer models. Reported mechanisms include modulation of PI3K/AKT, MAPK, NF-κB, HIF-1α, ROS, apoptosis, and cell-cycle signaling. Clinical anticancer efficacy has not been established.

Alzheimer's Disease: Preclinical evidence suggests neuroprotective activity through antioxidant and anti-inflammatory effects, reduction of neuronal injury, regulation of oxidative stress and mitochondrial function, and modulation of signaling pathways relevant to cognitive impairment and amyloid-associated neurotoxicity. Clinical efficacy for Alzheimer's disease has not been established.



NRF2, nuclear factor erythroid 2-related factor 2: Click to Expand ⟱
Source: TCGA
Type: Antiapoptotic
Nrf2 is responsible for regulating an extensive panel of antioxidant enzymes involved in the detoxification and elimination of oxidative stress. Thought of as "Master Regulator" of antioxidant response.
-One way to estimate Nrf2 induction is through the expression of NQO1.
NQO1, the most potent inducer:
SFN 0.2 μM,
quercetin (2.5 μM),
curcumin (2.7 μM),
Silymarin (3.6 μM),
tamoxifen (5.9 μM),
genistein (6.2 μM ),
beta-carotene (7.2μM),
lutein (17 μM),
resveratrol (21 μM),
indol-3-carbinol (50 μM),
chlorophyll (250 μM),
alpha-cryptoxanthin (1.8 mM),
and zeaxanthin (2.2 mM)

1. Raising Nrf2 enhances the cell's antioxidant defenses and ↓ROS. This strategy is used to decrease chemo-radio side effects.
2. Downregulating Nrf2 lowers antioxidant defenses and ↑ROS. In cancer cells this leads to DNA damage, and cell death.
3. However there are some cases where increasing Nrf2 paradoxically causes an increase in ROS (cancer cells). Such as cases of Mitochondial overload, signal crosstalk, reductive stress

-In some cases, Nrf2 is overexpressed in cancer cells, which can lead to the activation of genes involved in cell proliferation, angiogenesis, and metastasis. This can contribute to the development of resistance to chemotherapy and targeted therapies.
-Increased Nrf2 expression: Lung, Breast, Colorectal, Prostrate.
Decreased Nrf2 expression: Skine, Liver, Pancreatic.
-Nrf2 is a cytoprotective transcription factor which demonstrated both a negative effect as well as a positive effect on cancer
- "promotes Nrf2 translocation from the cytoplasm to the nucleus," means facilitates the movement of Nrf2 into the nucleus, thereby enhancing the cell's antioxidant and cytoprotective responses. -Major regulator of Nrf2 activity in cells is the cytosolic inhibitor Keap1.

Nrf2 Inhibitors and Activators
Nrf2 Inhibitors: Brusatol, Luteolin, Trigonelline, VitC, Retinoic acid, Chrysin
Nrf2 Activators: SFN, OPZ EGCG, Resveratrol, DATS, CUR, CDDO, Api
- potent Nrf2 inducers from plants include sulforaphane, curcumin, EGCG, resveratrol, caffeic acid phenethyl ester, wasabi, cafestol and kahweol (coffee), cinnamon, ginger, garlic, lycopene, rosemany

Nrf2 plays dual roles in that it can protect normal tissues against oxidative damage and can act as an oncogenic protein in tumor tissue.
– In healthy tissues, NRF2 activation helps protect cells from oxidative damage and maintains cellular homeostasis.
– In many cancers, constitutive activation of NRF2 (often through mutations in NRF2 itself or loss-of-function mutations in KEAP1) leads to an enhanced antioxidant capacity.
– This upregulation can promote tumor cell survival by enabling cancer cells to thrive under oxidative stress, resist chemotherapeutic agents, and sustain metabolic reprogramming.
– Elevated NRF2 levels have been implicated in promoting tumor growth, metastasis, and resistance to therapy in various malignancies.
– High or sustained NRF2 activity is frequently associated with aggressive tumor phenotypes, poorer prognosis, and decreased overall survival in several cancer types.
– While its activation is essential for protecting normal cells from oxidative stress, aberrant or sustained NRF2 activation in tumor cells can lead to enhanced survival, therapeutic resistance, and tumor progression.

NRF2 inhibitors: (to decrease antioxidant defenses and increase cell death from ROS).
-Brusatol: most cited natural inhibitors of Nrf2.
-Luteolin: luteolin can reduce Nrf2 activity in specific cancer models and may enhance cell sensitivity to chemotherapy. However, luteolin is also known as an antioxidant, and its influence on Nrf2 can sometimes be context dependent.
-Apigenin: certain studies to down‑regulate Nrf2 in cancer cells: Dose and context dependent .
-Oridonin:
-Wogonin: although its effects might be cell‑ and dose‑specific.
- Withaferin A

Scientific Papers found: Click to Expand⟱
7897- IVT,  VT,    Vitexin and isovitexin delayed ageing and enhanced stress-resistance through the activation of the SKN-1/Nrf2 signaling pathway
- in-vitro, Nor, NA
*antiOx↑, *ROS↓, *OS↑, *NRF2↑, *AntiAg↑,
7913- VT,    Review of the effects of vitexin in oxidative stress-related diseases
*antiOx↑, *ROS↓, *lipid-P↓, *memory↑, *Stroke↓, *cardioP↑, *neuroP↑, *Inflam↓, *NRF2↑, *HO-1↑, *NQO1↑, *GRP78/BiP↑, *CHOP/DDIT3↓, *BACE/β-secretase↓, *ChE↓, *AChE↓, *BChE↓, *GSH↑, *TNF-α↓, *IL1β↓, *IL6↓, *IL33↓, *LDH↓, *MDA↓, *SOD↑,
7902- VT,    Vitexin Protects Against Scopolamine-Induced Cognitive Impairment by Preserving Synaptic Integrity and Modulating Nrf2/HO-1 and NF-κB Signaling Pathways
- in-vivo, AD, NA
*Dose↝, *Learn↑, *memory↑, *AChE↓, *lipid-P↓, *TOS↓, *MDA↓, *ONOO↓, *NO↓, *NOS2↓, *TAC↑, *BDNF↑, *GDNF↑, *PSD95↑, *GFAP↓, *NF-kB↓, *COX2/PTGS2↓, *NRF2↑, *HO-1↑, *neuroP↑, *NeuroI↓,
7887- VT,  IVT,    Dietary Flavonoids Vitexin and Isovitexin: New Insights into Their Functional Roles in Human Health and Disease Prevention
- Review, AD, NA - Review, Var, NA
*antiOx↑, *Inflam↓, *AntiCan↑, *Bacteria↓, *neuroP↑, *Obesity↓, *cardioP↑, *ROS↓, *MMP↑, *ATP↑, *MFN2↑, *DRP1/DNM1L↓, *FOXO3↑, *NRF2↑, *Ferroptosis↓, *GPx4↑, TumCP↓, HMGB1↓, PI3K↓, Akt↓, Hif1a↓, CDK1↓, CycB/CCNB1↓, TumCCA↑, Apoptosis↑, P53↑, NF-kB↓, ERK↓, p‑PI3K↓, miR-34a↑, Apoptosis↑, CSCs?, *MAPK↓, *HO-1↑, *hepatoP↑, *AMPK↑, *Akt↑, *GSK‐3β↑, *chemoP↑, *Casp3↓, *IRes↝, *GlucoseCon↑, ChemoSen↑, *GSH↑, *SOD↑, *ATF2↑, *GPx↑, *GSTs↑, *AntiAge↑, *Stroke↓, *AChE↓, *ACE/ACE1↓, *ACE2↓, *GutMicro↑, *MPO↓, *H+/K+-ATPase↓, *AntiDiabetic↑, *GLUT4↑, *Obesity↓, *HH↓, *RenoP↑, *BioAv↓, *BioAv↝, *BioAv↑,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death(tgid=5)

Akt↓, 1,   Apoptosis↑, 2,  

DNA Damage & Repair(tgid=10)

P53↑, 1,  

Cell Cycle & Senescence(tgid=11)

CDK1↓, 1,   CycB/CCNB1↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12)

CSCs?, 1,   ERK↓, 1,   miR-34a↑, 1,   PI3K↓, 1,   p‑PI3K↓, 1,  

Migration(tgid=13)

TumCP↓, 1,  

Angiogenesis & Vasculature(tgid=14)

Hif1a↓, 1,  

Immune & Inflammatory Signaling(tgid=16)

HMGB1↓, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance(tgid=21)

ChemoSen↑, 1,  
Total Targets: 16

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0)

ACE/ACE1↓, 1,   ACE2↓, 1,   GDNF↑, 1,   GFAP↓, 1,   H+/K+-ATPase↓, 1,   IRes↝, 1,   Learn↑, 1,   NeuroI↓, 1,   ONOO↓, 1,   Stroke↓, 2,  

Redox & Oxidative Stress(tgid=1)

antiOx↑, 3,   Ferroptosis↓, 1,   GPx↑, 1,   GPx4↑, 1,   GSH↑, 2,   GSTs↑, 1,   HO-1↑, 3,   lipid-P↓, 2,   MDA↓, 2,   MFN2↑, 1,   MPO↓, 1,   NQO1↑, 1,   NRF2↑, 4,   ROS↓, 3,   SOD↑, 2,   TAC↑, 1,   TOS↓, 1,  

Mitochondria & Bioenergetics(tgid=3)

ATP↑, 1,   DRP1/DNM1L↓, 1,   MMP↑, 1,  

Core Metabolism/Glycolysis(tgid=4)

AMPK↑, 1,   GlucoseCon↑, 1,   LDH↓, 1,  

Cell Death(tgid=5)

Akt↑, 1,   ATF2↑, 1,   Casp3↓, 1,   Ferroptosis↓, 1,   MAPK↓, 1,  

Protein Folding & ER Stress(tgid=8)

CHOP/DDIT3↓, 1,   GRP78/BiP↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12)

FOXO3↑, 1,   GSK‐3β↑, 1,   HH↓, 1,  

Migration(tgid=13)

AntiAg↑, 1,  

Angiogenesis & Vasculature(tgid=14)

NO↓, 1,  

Barriers & Transport(tgid=15)

GLUT4↑, 1,  

Immune & Inflammatory Signaling(tgid=16)

COX2/PTGS2↓, 1,   IL1β↓, 1,   IL33↓, 1,   IL6↓, 1,   Inflam↓, 2,   NF-kB↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission(tgid=18)

AChE↓, 3,   BChE↓, 1,   BDNF↑, 1,   ChE↓, 1,   PSD95↑, 1,  

Protein Aggregation(tgid=19)

BACE/β-secretase↓, 1,  

Drug Metabolism & Resistance(tgid=21)

BioAv↓, 1,   BioAv↑, 1,   BioAv↝, 1,   Dose↝, 1,  

Clinical Biomarkers(tgid=22)

GutMicro↑, 1,   IL6↓, 1,   LDH↓, 1,   NOS2↓, 1,  

Functional Outcomes(tgid=23)

AntiAge↑, 1,   AntiCan↑, 1,   AntiDiabetic↑, 1,   cardioP↑, 2,   chemoP↑, 1,   hepatoP↑, 1,   memory↑, 2,   neuroP↑, 3,   Obesity↓, 2,   OS↑, 1,   RenoP↑, 1,  

Infection & Microbiome(tgid=24)

Bacteria↓, 1,  
Total Targets: 79

Scientific Paper Hit Count for: NRF2, nuclear factor erythroid 2-related factor 2
4 Vitexin
2 Isovitexin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:462  Target#:226  State#:%  Dir#:2
wNotes=0 sortOrder:rid,rpid

 

Home Page